Zacks Small Cap Research on MSN
EDSA: EB05 Reduces Risk of Death 25% in Phase 3 ARDS Trial…
EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Positive Phase 3 Results for EB05 in ARDS On October 28, 2025, Edesa ...
Topline data were announced from 2 replicate phase 3 studies evaluating upadacitinib in adults and adolescents with nonsegmental vitiligo.
FutureWise Research today announced the launch of its comprehensive new report, Dermatology Treatment Devices Market by Type, ...
13hon MSN
NHS approves revolutionary new treatment for debilitating skin condition affecting thousands
The twice-a-day cream can be used by adults affected by the inflammatory condition, which causes uncomfortable patches of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback